We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Moderate to Severe Atopic Dermatitis Study

This study is currently closed to enrollment.

Controlled Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis

woman scratching her hand

 

AGE: 18-55 years old
SEX AT BIRTH: All
TYPE: Investigational Treatment Study
CONDITION: Atopic Dermatitis (Eczema)
HEALTHY PARTICIPANTS: No
LOCATION: UH Cleveland Medical Center

Study Purpose

The purpose of this study is to evaluate the impact of lebrikizumab on vaccine responses (TDaP and meningococcal) in patients with moderate-to-severe Atopic Dermatitis. This study will further assess the efficacy and safety of lebrikizumab in patients with AD.


STUDY ID#

  • STUDY20201892